These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28219253)

  • 1. In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
    Huang C; Li NM; Gao P; Yang S; Ning Q; Huang W; Li ZP; Ye PJ; Xiang L; He DX; Tan XW; Yu CY
    Drug Deliv; 2017 Nov; 24(1):459-466. PubMed ID: 28219253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
    Cheng M; Liu Z; Wan T; He B; Zha B; Han J; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
    Cancer Biol Ther; 2012 Dec; 13(14):1407-16. PubMed ID: 22954702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
    Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
    ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
    Chen S; Ouyang H; He D; Liu D; Wang X; Chen H; Pan W; Li Q; Xie W; Yu C
    Curr Pharm Des; 2022; 28(25):2113-2125. PubMed ID: 35524673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
    Xiang Y; Huang W; Huang C; Long J; Zhou Y; Liu Y; Tang S; He DX; Tan XW; Wei H; Yu CY
    Mol Pharm; 2020 Sep; 17(9):3223-3235. PubMed ID: 32658485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
    Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
    World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy.
    Yu CY; Wang YM; Li NM; Liu GS; Yang S; Tang GT; He DX; Tan XW; Wei H
    Mol Pharm; 2014 Feb; 11(2):638-44. PubMed ID: 24383625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-Cysteine conjugated poly L-lactide nanoparticles containing 5-fluorouracil: formulation, characterization, release and uptake by tissues in vivo.
    Mishra BJ; Kaul A; Trivedi P
    Drug Deliv; 2015 Feb; 22(2):214-22. PubMed ID: 24524408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
    Cheng M; He B; Wan T; Zhu W; Han J; Zha B; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
    PLoS One; 2012; 7(10):e47115. PubMed ID: 23077553
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Sun R; Fang L; Lv X; Fang J; Wang Y; Chen D; Wang L; Chen J; Qi Y; Tang Z; Zhang J; Tian Y
    Drug Deliv; 2021 Dec; 28(1):2071-2084. PubMed ID: 34595970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma.
    Babaei M; Abnous K; Taghdisi SM; Amel Farzad S; Peivandi MT; Ramezani M; Alibolandi M
    Nanomedicine (Lond); 2017 Jun; 12(11):1261-1279. PubMed ID: 28520529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer.
    Li T; Chen X; Liu Y; Fan L; Lin L; Xu Y; Chen S; Shao J
    Eur J Pharm Sci; 2017 Jan; 96():456-463. PubMed ID: 27771513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.
    Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q
    Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
    Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
    Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.
    Huang Y; Hu L; Huang S; Xu W; Wan J; Wang D; Zheng G; Xia Z
    Int J Nanomedicine; 2018; 13():8309-8323. PubMed ID: 30584302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
    Cheng M; Ma D; Zhi K; Liu B; Zhu W
    Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apocynin-loaded PLGA nanomedicine tailored with galactosylated chitosan intrigue asialoglycoprotein receptor in hepatic carcinoma: Prospective targeted therapy.
    Anter HM; Aman RM; Othman DIA; Elamin KM; Hashim IIA; Meshali MM
    Int J Pharm; 2023 Jan; 631():122536. PubMed ID: 36572262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cytotoxic and apoptotic potential in hepatic carcinoma cells of chitosan nanoparticles loaded with ginsenoside compound K.
    Zhang J; Wang Y; Jiang Y; Liu T; Luo Y; Diao E; Cao Y; Chen L; Zhang L; Gu Q; Zhou J; Sun F; Zheng W; Liu J; Li X; Hu W
    Carbohydr Polym; 2018 Oct; 198():537-545. PubMed ID: 30093032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
    Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
    Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma.
    Huang M; Liu J; Fan Y; Sun J; Cheng JX; Zhang XF; Zhai BT; Guo DY
    Int J Biol Macromol; 2023 Dec; 253(Pt 6):127219. PubMed ID: 37802456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.